Autoimmune hepatitis is a chronic condition in which your immune system mistakenly attacks your own liver cells, causing inflammation that can eventually lead to scarring and liver damage. It affects roughly 17 to 30 people per 100,000 in North America and Europe, and without treatment, it can progress to cirrhosis. With treatment, however, the 10-year survival rate is over 80%.
How Autoimmune Hepatitis Develops
In a healthy immune system, T cells learn to distinguish between foreign invaders and the body’s own tissues. In autoimmune hepatitis, that tolerance breaks down. T cells begin targeting liver cells (hepatocytes) as though they were threats, triggering chronic inflammation. Over time, repeated cycles of inflammation and repair can produce fibrosis, the buildup of scar tissue that stiffens the liver and impairs its function.
The process appears to require two ingredients: a genetic predisposition and some kind of environmental trigger. Certain gene variants on chromosome 6, specifically within the immune system’s cell-identification machinery, make some people more vulnerable. The exact triggers aren’t fully identified, but infections, medications, and toxins have all been proposed as sparks that set the immune response in motion in someone whose genetics make them susceptible.
Type 1 vs. Type 2
Autoimmune hepatitis comes in two forms, distinguished mainly by which antibodies show up in blood tests and who tends to get it.
Type 1 is the more common form and typically appears in adulthood. It’s associated with anti-nuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA). About 28 to 33% of people with Type 1 already have cirrhosis by the time they’re diagnosed, which speaks to how quietly the disease can progress.
Type 2 usually appears in childhood or the early teenage years and is associated with a different set of antibodies: anti-liver/kidney microsome type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1). Cirrhosis at diagnosis is rare in Type 2, partly because younger patients tend to come to medical attention sooner and partly because the disease pattern differs.
Common Symptoms
Many people with autoimmune hepatitis have no symptoms at all. The condition is often discovered incidentally when routine blood work reveals abnormal liver enzymes. For those who do have symptoms, the most common include fatigue, joint pain, nausea, poor appetite, and a dull ache in the upper right abdomen where the liver sits.
More visible signs can include jaundice (a yellowish tint to the skin and whites of the eyes), dark urine, and pale stools. Some people develop skin conditions like rashes, psoriasis, vitiligo, or acne. In cases where the disease has silently progressed to cirrhosis before being caught, the first symptoms may be those of advanced liver disease: persistent weakness, fluid retention in the abdomen, or easy bruising.
How It’s Diagnosed
Diagnosis relies on a combination of blood tests, imaging, and usually a liver biopsy. No single test confirms autoimmune hepatitis on its own, so doctors use a scoring system that weighs several factors together.
Blood tests look for specific autoantibodies (ANA, ASMA, or anti-LKM1) and measure immunoglobulin G (IgG), a type of antibody that tends to be elevated in this condition. Elevated liver enzymes signal ongoing inflammation. Each of these findings earns points in the diagnostic scoring system, and a high enough score makes the diagnosis probable or definite.
A liver biopsy provides the most direct evidence. Under a microscope, autoimmune hepatitis has a characteristic look: dense clusters of immune cells, particularly plasma cells, crowd into the portal tracts (the connective tissue channels inside the liver). These immune cells spill past their normal boundaries and invade the surrounding liver tissue, a pattern called interface hepatitis. In more severe cases, there’s visible death of liver cells and early scar formation. A distinctive feature is emperipolesis, where attacking T cells physically penetrate liver cells to destroy them.
Progression and Long-Term Outlook
Untreated autoimmune hepatitis tends to get worse over time. In one large study of more than 450 patients, 30% already had cirrhosis at the time of diagnosis. An additional 10% developed cirrhosis over a median follow-up of about seven years, even with medical care. Another study found that 20% of patients developed cirrhosis within roughly four years of follow-up.
These numbers underscore the importance of treatment and monitoring, but the overall outlook is encouraging. With appropriate therapy, the 10-year survival rate exceeds 80%. For those who eventually need a liver transplant, five-year patient survival after transplant is around 90%, and five-year graft survival (meaning the transplanted liver continues to function) is about 75%.
Treatment Options
The goal of treatment is to suppress the immune attack on the liver and bring inflammation under control. The standard approach uses corticosteroids (to quickly reduce inflammation) combined with another immune-suppressing medication that allows the steroid dose to be lowered over time. Most people respond well to this combination, and many achieve biochemical remission, meaning their liver enzymes return to normal.
For patients without cirrhosis, a liver-targeted steroid called budesonide is an alternative to the traditional systemic steroid (prednisone). A systematic review of randomized trials and comparative studies found that budesonide achieves similar remission rates to prednisone at both 6 and 12 months. The key advantage is fewer side effects, particularly the cosmetic ones that many patients find distressing: weight gain concentrated in the face, acne, and thinning skin. Budesonide is not suitable for people who already have cirrhosis because the scarred liver can’t process it properly.
Treatment is typically long-term. Some people can eventually taper off medication after achieving sustained remission, but relapse rates are high, and many need ongoing low-dose therapy for years or indefinitely.
Protecting Your Bones on Steroids
Long-term corticosteroid use carries a real risk of bone density loss, which can progress from osteopenia (mild thinning) to osteoporosis (significant weakening that raises fracture risk). If you’re on corticosteroids for autoimmune hepatitis, calcium and vitamin D supplements are commonly recommended to help preserve bone strength. The specific doses depend on your age, baseline bone density, and other medications, so your doctor will tailor the recommendation.
Diet and Lifestyle Considerations
No specific diet has been shown to cause, prevent, or treat autoimmune hepatitis. That said, eating a well-balanced diet supports overall liver health and becomes especially important if the disease progresses to cirrhosis, when the liver’s ability to process nutrients is compromised. Avoiding alcohol is a practical step, since alcohol adds an extra source of liver inflammation on top of the autoimmune damage. Maintaining a healthy weight matters too, because excess fat deposits in the liver (fatty liver disease) can compound the injury.
Beyond diet, staying current with vaccinations for hepatitis A and B is important if you haven’t already been immunized, since a viral hepatitis infection on top of autoimmune hepatitis could cause serious harm to an already stressed liver. Regular monitoring through blood tests and periodic imaging helps catch any progression early, when adjustments to treatment can make the biggest difference.